Cowen and Company’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cowen and Company’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5,500	Closed	-$141K	–	664
2022 Q2	$141K	Sell	5,500 -5,000	-48%	-$709K	0.01%	222
2022 Q1	$70K	Buy	+10,500	New	+$1.6M	0.01%	305
2021 Q4	–	Sell	-15,000	Closed	-$48K	–	639
2021 Q3	$48K	Sell	15,000 -400	-3%	-$75K	﹤0.01%	390
2021 Q2	$67K	Buy	15,400 +10,400	+208%	+$1.52M	﹤0.01%	375
2021 Q1	$18K	Buy	+5,000	New	+$752K	﹤0.01%	456

Other funds holding ALNY

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Cowen and Company's ALNY Position: Q2 2022 in Review

Cowen and Company sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2022, closing a stake of 436 shares — an estimated $61.9K sold.

Cowen and Company first reported a position in ALNY in Q1 2021 and held it in 2 quarters. The position peaked at $71K in Q1 2022. 422 funds tracked by Wall St. Rank hold ALNY as of Q2 2022.

Cowen and Company reported no remaining Alnylam Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Cowen and Company sold 436 Alnylam Pharmaceuticals shares in Q2 2022, an estimated $61.9K.
Cowen and Company first reported a position in Alnylam Pharmaceuticals in Q1 2021 and held it in 2 quarters.
Cowen and Company's Alnylam Pharmaceuticals position peaked at $71K in Q1 2022.
422 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2022.

Based on Cowen and Company's 13F filing for Q2 2022, filed 5 Aug 2022.